Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H14N4O |
Molecular Weight | 266.2979 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=NC2=C1NC(=O)C3=C(N=CC=C3)N2C4CC4
InChI
InChIKey=NQDJXKOVJZTUJA-UHFFFAOYSA-N
InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
Molecular Formula | C15H14N4O |
Molecular Weight | 266.2979 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00238Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nevirapine.html
Sources: http://www.drugbank.ca/drugs/DB00238
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nevirapine.html
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time. Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. Nevirapine is used for use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22514580
Curator's Comment: Nevirapine (NVP) crosses well the BBB
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL614530 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26086472 |
239.0 µM [EC50] | ||
Target ID: CHEMBL378 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25240095 |
0.31 nM [EC50] | ||
Target ID: CHEMBL247 Sources: http://www.drugbank.ca/drugs/DB00238 |
250.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Viramune Approved UseVIRAMUNE is an NNRTI indicated for combination antiretroviral treatment of HIV-1 infection Launch Date1995 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2060 ng/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
82000 ng × h/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
96700 ng × h/mL |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED |
|
161000 ng × h/mL |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
45 h |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40% |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEVIRAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg single, oral Overdose |
unhealthy, 8-days-old n = 1 Health Status: unhealthy Age Group: 8-days-old Sex: F Population Size: 1 Sources: |
Other AEs: Neutropenia, Hyperlactatemia... |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Disc. AE: Rash, Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: Page: p. 56Stevens-Johnson syndrome (1%) Transaminases increased (1%) ALT increased (1%) GGT increased (<1%) AST increased (<1%) Hepatic enzyme increased (<1%) Hepatitis (1%) Hepatotoxicity (1%) Hepatitis acute (<1%) Hepatitis toxic (<1%) Nausea (1%) Malaise (1%) Pyrexia (1%) Fatigue (1%) Vascular disorders (<1%) |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Disc. AE: Rash, Drug rash with eosinophilia and systemic symptoms... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: Page: p. 56Drug rash with eosinophilia and systemic symptoms (<1%) Transaminases increased (1%) ALT increased (<1%) GGT increased (<1%) AST increased (<1%) Hepatic enzyme increased (<1%) Hepatitis (1%) Hepatotoxicity (<1%) Hepatitis acute (<1%) Hepatitis toxic (<1%) Nausea (<1%) Malaise (<1%) Pyrexia (<1%) Fatigue (<1%) Vascular disorders (<1%) Musculoskeletal and connective tissue disorders (<1%) |
800 mg 1 times / day multiple, oral Overdose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Hepatotoxicity, Reaction skin... AEs leading to discontinuation/dose reduction: Hepatotoxicity (grade 5) Sources: Reaction skin (severe) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hyperlactatemia | 200 mg single, oral Overdose |
unhealthy, 8-days-old n = 1 Health Status: unhealthy Age Group: 8-days-old Sex: F Population Size: 1 Sources: |
|
Neutropenia | mild | 200 mg single, oral Overdose |
unhealthy, 8-days-old n = 1 Health Status: unhealthy Age Group: 8-days-old Sex: F Population Size: 1 Sources: |
ALT increased | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Fatigue | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatitis | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatotoxicity | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Malaise | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Nausea | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Pyrexia | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Stevens-Johnson syndrome | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Transaminases increased | 1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Rash | 2% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
AST increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
GGT increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatic enzyme increased | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatitis acute | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatitis toxic | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Vascular disorders | <1% Disc. AE |
200 mg 2 times / day steady, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: steady Dose: 200 mg, 2 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 506 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 506 Sources: Page: p. 56 |
Hepatitis | 1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Transaminases increased | 1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Rash | 2% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
ALT increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
AST increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Drug rash with eosinophilia and systemic symptoms | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Fatigue | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
GGT increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Hepatic enzyme increased | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Hepatitis acute | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Hepatitis toxic | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Hepatotoxicity | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Malaise | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Musculoskeletal and connective tissue disorders | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Nausea | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Pyrexia | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Vascular disorders | <1% Disc. AE |
400 mg 1 times / day steady, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: Page: p. 56 |
unhealthy, >18 years n = 505 Health Status: unhealthy Age Group: >18 years Sex: M+F Population Size: 505 Sources: Page: p. 56 |
Hepatotoxicity | grade 5 Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Reaction skin | severe Disc. AE |
200 mg 1 times / day steady, oral Recommended Dose: 200 mg, 1 times / day Route: oral Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase. | 1999 |
|
A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group. | 1999 Oct 1 |
|
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. | 2000 Apr 10 |
|
Didanosine-induced hepatitis. | 2000 Aug |
|
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. | 2000 Aug |
|
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. | 2000 Jul |
|
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients. | 2000 Jun 10 |
|
Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agents. | 2000 Mar |
|
[Methadone withdrawal syndrome induced by nevirapine]. | 2000 Mar 18 |
|
Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. | 2000 May |
|
Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine. | 2000 May |
|
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. | 2000 May 18 |
|
Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations. | 2000 May 4 |
|
Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. | 2000 Oct 19 |
|
Piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thiourea compounds with potent anti-HIV activity. | 2000 Sep |
|
Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase. | 2000 Sep 18 |
|
A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. | 2001 |
|
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. | 2001 |
|
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. | 2001 Apr |
|
Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription. | 2001 Apr |
|
Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting. | 2001 Apr 13 |
|
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. | 2001 Apr 13 |
|
Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine. | 2001 Apr 15 |
|
[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor]. | 2001 Apr 2 |
|
Antiviral drugs: current state of the art. | 2001 Aug |
|
Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. | 2001 Feb |
|
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. | 2001 Feb |
|
Indian company offers cheap anti-AIDS drugs. | 2001 Feb 15 |
|
Nevirapine and postexposure prophylaxis for human immunodeficiency virus. | 2001 Feb 21 |
|
Simple and rapid determination of nevirapine in human serum by reversed-phase high-performance liquid chromatography. | 2001 Feb 25 |
|
Prevention of nevirapine-associated rash. | 2001 Feb 3 |
|
Ritonavir-induced carbamazepine toxicity. | 2001 Jan |
|
Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations. | 2001 Jan 18 |
|
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. | 2001 Jan 20 |
|
Need for increased dose of warfarin in HIV patients taking nevirapine. | 2001 Jan 26 |
|
New developments in anti-HIV chemotherapy. | 2001 Jan-Feb |
|
Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors. | 2001 Jul |
|
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. | 2001 Jul 1 |
|
Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease. | 2001 Jun |
|
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. | 2001 Jun |
|
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine. | 2001 Jun |
|
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. | 2001 Jun 15 |
|
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). | 2001 Jun 15 |
|
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. | 2001 Mar 1 |
|
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. | 2001 Mar 1 |
|
Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. | 2001 Mar 3 |
|
Sequencing antiretroviral drugs. | 2001 Mar 30 |
|
[Cutaneous adverse events related to simultaneous nevirapine treatment and pneumococcal vaccination in HIV-infected patients]. | 2001 Mar 31 |
|
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. | 2001 May 4 |
|
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. | 2001 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/nevirapine.html
The recommended dose for Nevirapine is one 200 mg tablet daily for the first 14 days, followed by one 200 mg tablet twice daily, in combination with other antiretroviral agents.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16752922
The IC50 value for inhibition by nevirapine against immunodeficiency virus type 1 (HIV) nucleoside reverse transcriptase (RT) in removal assay was 3 uM
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:31:21 GMT 2023
by
admin
on
Fri Dec 15 15:31:21 GMT 2023
|
Record UNII |
99DK7FVK1H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
NEVIRAPINE TEVA (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
NCI_THESAURUS |
C97453
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
WHO-ATC |
J05AR05
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
WHO-VATC |
QJ05AG01
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
NDF-RT |
N0000175463
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
VIRAMUNE (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
LIVERTOX |
NBK548895
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.2
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
WHO-VATC |
QJ05AR07
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
NDF-RT |
N0000009948
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
NDF-RT |
N0000175460
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (LAM/NEV/STA)
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
WHO-ATC |
J05AG01
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
FDA ORPHAN DRUG |
293409
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (LAM/NEV/ZID)
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
WHO-VATC |
QJ05AR05
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
||
|
WHO-ATC |
J05AR07
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09214MIG
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
N0000190118
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | Cytochrome P450 3A Inducers [MoA] | ||
|
DTXSID7031797
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
53654
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
Nevirapine
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
SUB25191
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
1460703
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
63613
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
6815
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
NEVIRAPINE
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL57
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
100000085470
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
99DK7FVK1H
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
D019829
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
m7845
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | Merck Index | ||
|
641530
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
129618-40-2
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
NEVIRAPINE
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | Description: A white to almost white powder. Solubility: Practically insoluble in water, sparingly to slightly soluble in dichloromethane R, slightly soluble in methanol R. Category: Antiretroviral (Non-Nucleoside Reverse Transcriptase Inhibitor). Storage: Nevirapine should be kept in a well-closed container. Labelling: The designation on the container should state whether the substance is the hemihydrate or is in the anhydrous form. Definition: Nevirapine contains not less than 98.0% and not more than 102.0% of nevirapine (C15H14N4O), calculated with reference to the anhydrous substance. | ||
|
DB00238
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
1904
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
DD-19
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
C29277
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
4463
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
7164
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | |||
|
N0000187064
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY | Cytochrome P450 2B6 Inducers [MoA] | ||
|
99DK7FVK1H
Created by
admin on Fri Dec 15 15:31:21 GMT 2023 , Edited by admin on Fri Dec 15 15:31:21 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SOLVATE->ANHYDROUS |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
SUBSTANCE->BASIS OF STRENGTH |
|
||
|
TARGET ORGANISM->INHIBITOR |
IC50 values (50% inhibitory
concentration) ranged from 10-100 nM against laboratory and clinical isolates of HIV-1.
IC50
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
This reactive intermediate was catalyzed
primarily by CYP3A and possibly by CYP2D6, CYP2C19,
and CYP2A6
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
Amount NOT SPECIFIED
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
The test is not valid unless the resolution between nevirapine and nevirapine impurity B RS is not less than 5. In the chromatogram obtained with solution (3) the peak due to impurity (B) is eluted at a relative retention of about 0.7 with reference to nevirapine (retention time about 7.6 minutes).
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Amount NOT SPECIFIED
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||